On-label use of revumenib in KMT2A-rearranged leukemia and late-phase trials of both agents in NPM1-mutated disease have shifted the field toward combination strategies in frontline and salvage settings (Loo et al., 2024). This evidence concerns the gene NPM1 and leukemia.